Navigation

First publication of terminated technology appraisals

NICE was unable to recommend several treatments that were being assessed using its single technology appraisal process (STA) in June, due to the lack of - or inadequate - manufacturer evidence submissions.

So far NICE has published 25 single technology appraisals on the use of drugs like Herceptin (for early breast cancer) and alteplase for the treatment of acute ischaemic stroke. The process waslaunched in 2005, to sit alongside - and speed up - its standardappraisal method. It focuses on drugs and other treatments that have been licensed or which have just become available.

The process relies on manufacturers submitting evidence, in line with our specification. When, occasionally, they fail to make a submission or it does not meet the specification, we work with manufacturers to resolve the problem. This month, for the first time, it was not possible to carry out full appraisals on four treatments, due to insufficient evidence from the manufacturer.

NICE was unable to recommend the following for this reason:

  • bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer
  • bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology)
  • carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated
  • cetuximab for the treatment of colorectal cancer following failure of oxaliplatin-containing chemotherapy

NICE is asking NHS organisations to take into account the reasons why the manufacturer did not make an evidence submission when making local decisions on whether to offer the treatment (these can be found within the guidance documents).

If sufficient evidence does become available, we may take the opportunity to review our advice to the NHS.

More information can be found here

This page was last updated: 19 April 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.